Q2 2025 Granules India Ltd Earnings Call Transcript
Key Points
- Granules India Ltd (BOM:532482) maintained healthy margins despite a voluntary pause in manufacturing, driven by strong sales of formulations and a favorable product mix.
- The company resumed dispatches in late September and began a phased restart of manufacturing operations in October, indicating a recovery from the temporary pause.
- Granules India Ltd is enhancing its organizational structure by appointing new leadership in operations and manufacturing to strengthen its quality culture.
- The company is focusing on new product launches from its GPI site in the US market, particularly in the CNS and ADHD segments, which are expected to drive future growth.
- Granules India Ltd has made significant progress in its R&D efforts, with increased spending and a growing list of product approvals globally, demonstrating a strong commitment to innovation.
- The voluntary pause in manufacturing and distribution at the Gagillapur facility impacted sales, leading to a 19% decline in revenue compared to Q2 FY24.
- The US FDA inspection at the Gagillapur facility resulted in six form 483 observations, requiring corrective actions and initiatives to address these issues.
- The API and PFI segments experienced reduced contributions due to price erosion and softer demand, particularly for paracetamol, affecting overall performance.
- The company's net debt remained high at INR7,973 million, indicating financial pressure despite operational improvements.
- The cash-to-cash cycle increased to 213 days, reflecting operational inefficiencies and challenges in managing working capital effectively.
Conference call of Granules, India Limited. Will begin shortly. Please stay connected. Thank you.
Ladies and gentlemen, Good day and welcome to the Q2 FY25 earnings conference call of Granules, India Limited. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call? (Operator instructions).
Please note that this conference is being recorded. I now hand the conference over to Mr. Irfan Raeen from Orient Capital. Thank you and over to you, sir.
Thank you on behalf of Granville Limited. I extend a warm welcome to all participants on Q2 and H1 FY25 financial discussion call. Today on the call, we have Dr. Krishna Prasad Chairman and managing director, Dr. KVS Rama Rao, Joint managing director and Chief Executive Officer, MS. Priyanka, Chigurupat, Executive director, Mr Mukesh Surana, Chief Financial Officer.
Before we begin the call, I would
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
